210 related articles for article (PubMed ID: 30968718)
21. Pritumumab, the first therapeutic antibody for glioma patients.
Babic I; Nurmemmedov E; Yenugonda VM; Juarez T; Nomura N; Pingle SC; Glassy MC; Kesari S
Hum Antibodies; 2018 Feb; 26(2):95-101. PubMed ID: 29036806
[TBL] [Abstract][Full Text] [Related]
22. Novel chemotherapeutics and other therapies for treating high-grade glioma.
Kang JH; Adamson C
Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791
[TBL] [Abstract][Full Text] [Related]
23. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
25. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
26. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.
Ma Q; Long W; Xing C; Chu J; Luo M; Wang HY; Liu Q; Wang RF
Front Immunol; 2018; 9():2924. PubMed ID: 30619286
[TBL] [Abstract][Full Text] [Related]
27. Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
Scutti JAB
Int J Oncol; 2018 Apr; 52(4):1041-1056. PubMed ID: 29484440
[TBL] [Abstract][Full Text] [Related]
28. Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
Uher O; Caisova V; Hansen P; Kopecky J; Chmelar J; Zhuang Z; Zenka J; Pacak K
Semin Oncol; 2019; 46(4-5):385-392. PubMed ID: 31739997
[TBL] [Abstract][Full Text] [Related]
29. Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top".
Simonelli M; Persico P; Perrino M; Zucali PA; Navarria P; Pessina F; Scorsetti M; Bello L; Santoro A
Cancer Treat Rev; 2018 Sep; 69():121-131. PubMed ID: 29966936
[TBL] [Abstract][Full Text] [Related]
30. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
31. Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy.
Dar TB; Henson RM; Shiao SL
Front Immunol; 2018; 9():3077. PubMed ID: 30692991
[TBL] [Abstract][Full Text] [Related]
32. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
33. Immune biological rationales for the design of combined radio- and immunotherapies.
Hader M; Frey B; Fietkau R; Hecht M; Gaipl US
Cancer Immunol Immunother; 2020 Feb; 69(2):293-306. PubMed ID: 31953578
[TBL] [Abstract][Full Text] [Related]
34. Targeting Innate Immunity in Glioma Therapy.
Gillard AG; Shin DH; Hampton LA; Lopez-Rivas A; Parthasarathy A; Fueyo J; Gomez-Manzano C
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256021
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in Gliomas.
Weant MP; Jesús CM; Yerram P
Semin Oncol Nurs; 2018 Dec; 34(5):501-512. PubMed ID: 30396808
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for brain tumors: understanding early successes and limitations.
Lieberman NAP; Vitanza NA; Crane CA
Expert Rev Neurother; 2018 Mar; 18(3):251-259. PubMed ID: 29322843
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
Sinnadurai M; McDonald KL
J Neurooncol; 2017 May; 132(3):359-372. PubMed ID: 28293764
[TBL] [Abstract][Full Text] [Related]
38. Principles of immunotherapy.
Liebelt BD; Finocchiaro G; Heimberger AB
Handb Clin Neurol; 2016; 134():163-81. PubMed ID: 26948354
[TBL] [Abstract][Full Text] [Related]
39. DNA Damage Repair in Brain Tumor Immunotherapy.
Zhao S; Xu B; Ma W; Chen H; Jiang C; Cai J; Meng X
Front Immunol; 2021; 12():829268. PubMed ID: 35095931
[TBL] [Abstract][Full Text] [Related]
40. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
